Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Pipeline Snapshot as of July 28, 2021
- Discovery Projects
- 29Phase 1
- 40Phase 2
- 23Phase 3
- 8Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-06482077 Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (adult) (E.U.) | Registration | New Molecular Entity | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S.; E.U.) (12 years of age and older) | Registration | New Molecular Entity | Vaccine |
TicoVac Therapeutic Area: Vaccines Phase:Registration Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Tick-borne encephalitis (TBE) (U.S.) | Registration | New Molecular Entity | Vaccine |
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Primary Clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) | Phase 3 | Product Enhancement | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults) | Phase 3 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) (FAST TRACK) | Phase 2 | New Molecular Entity | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-07307405 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Lyme disease (FAST TRACK) | Phase 2 | New Molecular Entity | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (maternal) | Phase 2 | Product Enhancement | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (children 2 to 11 years of age) | Phase 2 | Product Enhancement | Vaccine |
PF-07302048 (Covid-19 Vx) Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in collaboration with BioNTech) (infants 6 months to <24 months) | Phase 2 | Product Enhancement | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (infants)
Project advanced | Phase 2 | Product Enhancement | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (adult)
Project advanced | Phase 2 | Product Enhancement | Vaccine |
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 kinase inhibitor | ER+/HER2+ Metastatic Breast Cancer(PATINA) | Phase 3 | Product Enhancement | Small Molecule |
![iStock-1199449498_380x300[1].jpg](https://cdn.pfizer.com/pfizercom/styles/style_300_170/s3/2021-09/iStock-1199449498_380x300%5B1%5D.jpg?pYyJpQdhyvaU22v13JPyau8ro2rGk0CR&itok=pJGCW7Vt)
